Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

What Was Tested

In this phase 2 trial, researchers set out to test Petrelintide.

It had six arms (groups): one (experimental), one (placebo comparator), one (experimental), one (placebo comparator) and one (experimental).

Randomized participants will receive weekly subcutaneous injections of matching placebo to petrelintide.

The registry classes the interventions as drug and other.

Who Took Part

Enrollment: 221 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Male or female participants with body mass index (BMI) ≥27.0 kg/m2. Diagnosed with type 2 diabetes ≥180 days prior to the day of screening.

The full record lists 3 inclusion and 6 exclusion criteria; among the exclusions: severe hypoglycemia within 6 months prior to screening or history of hypoglycemia unawareness; receipt of any other glucose-lowering drug than those listed in the inclusion criterion within 90 days prior to screening; treatment with any medication (prescribed or over-the-counter) or alternative remedies (herbal or nutritional supplements) intended to promote weight loss within 90 days prior to screening.

How the Study Was Run

It was run as a randomized, parallel-group and double-blind study.

Random assignment meant chance, not the researchers, decided who got Petrelintide and who got the comparison, which limits bias.

The Petrelintide group and the comparison group ran side by side rather than switching.

As a double-blind Petrelintide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and investigator.

It started in 2025-04-22 with completion listed for 2026-08-13.

It ran at 48 sites in United States (48).

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Percentage Change in Body Weight (time frame: From Baseline (Day 1) to Weeks 28).

It also tracked 15 secondary outcomes, for example Change in Body Weight (kilogram), Change in Waist Circumference, Change in Glycated Hemoglobin (HbA1c), Change in Fasting Glucose, Change in High-Sensitivity C-reactive protein (hsCRP) and Changes in Fasting Lipids.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Petrelintide in 221 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Petrelintide compound page, all human trials.